Concepedia

Javier Agejas Francisco

JA

Statistics

Publications

1

Citations

57

H-Index

1

Active since

2015

Affiliations

Eli Lilly (United States)(Current)

Javier Agejas Francisco is an author at Eli Lilly (United States) specializing in molecular pharmacology, drug discovery, and metabolic syndrome.

Top concepts

MedicineBiochemistryPharmacologyDrug DiscoveryAtherosclerosisPharmacotherapyNatural SciencesVascular BiologyMetabolic SyndromeMedicinal Chemistry

Publications per year

2015–2015

1

Publications

1

Discovery of 6-(4-{[5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazol-4-yl]methoxy}piperidin-1-yl)-1-methyl-1<i>H</i>-indole-3-carboxylic Acid: A Novel FXR Agonist for the Treatment of Dyslipidemia

Michaël Génin, Ana B. Bueno, Javier Agejas Francisco et al. · Journal of Medicinal Chemistry · 2015 · 57 citations · Full text

Pharmaceutical Science, Selective Fxr Agonist, Farnesoid X Receptor +18

1–1 of 1